NANCY, France, Oct. 13, 2014 (GLOBE NEWSWIRE) -- Genclis, an innovative diagnostic company in the fields of allergy and cancer, announced today the appointment of Mr. Stéphane Boissel as CEO. His appointment as a Board Member will be proposed to the next Shareholder Meeting.
Dr. Bernard Bihain, MD, Founder and Chairman of the Board of Genclis, stated: "Genclis is today transitioning from an R&D company towards an integrated company with marketing, and sales with the goal of becoming rapidly profitable. The recruitment of Stéphane Boissel as CEO fits perfectly well in this context. He brings to us more than 20 years of successful international finance and business development credentials, all critical features for Genclis going forward".
Mr. Stéphane Boissel, CEO of Genclis, said: "Joining Genclis is a fantastic and exciting challenge. The team put together by Bernard Bihain pioneered the discovery of breakthroughs in the field of allergy and cancer diagnostics. This excellent science has now turned into concrete products. We will focus on achieving wide market acceptance of these products by rapidly confirming their clinical utility, while we also enrich our pipeline thanks to continuous innovative genomic R&D".
Prior to joining Genclis, Mr. Stéphane Boissel was EVP and CFO of Transgene (2010 to 2014). Prior to Transgene, Mr. Boissel worked at Innate Pharma, firstly as CFO and then as EVP and CFO (2002 to 2010). During his tenure at Transgene and Innate Pharma, he led several rounds of private and public placement totaling more than 150 million euros and negotiated several business deals in the US, EU and Asia. Mr. Boissel is or was a board member of several biotechnology companies, including Erytech Pharma and ElsaLys Biotech. He started his career at PWC (1990 to 1994). He then joined the investment banking group Lazard where he mostly worked in principal investment, in France, Singapore and Hong Kong (1994 to 2002). He under graduated in economics at the University of Lyon, graduated at Paris-Dauphine and then obtained his MBA from the Chicago Booth Graduate Business School. Stéphane is a French CFA (SFAF).
Genclis is an innovative genomic diagnostic company in the fields of allergy and cancer. Started in 2004, the Company initiated the commercialization of its allergy molecular diagnostic tests in 2014.
Genclis sells its products in French-speaking Europe through a dedicated platform: Galileo©. Galileo also distribute other allergy products from partners. Outside of its distribution zone, the Company sells its products through a distribution agreement with US-based Hycor, a rapidly emerging player in the field of allergy diagnostic.
In the field of cancer diagnostic, Genclis based its development on the concept of DNA/RNA transcription infidelity, an original, proprietary disruptive science. This science has already led to encouraging results in the severity prognostic of triple-negative breast cancer ("TNBC"), a very heterogeneous group of cancers including some types known to be very aggressive with poor prognosis. Genclis intends to rapidly achieve acceptance of its solution, Severidia©, as a standard for oncologists to offer their patients alternative treatment and monitoring options.
Stéphane Boissel, CEO: +33674780925 - firstname.lastname@example.org
Bernard Bihain, Chairman and CSO: +33633029088 - email@example.com
pr nomination Boissel Stéphane http://hugin.info/164309/R/1862614/653510.pdf
Source: Genclis SAS